In summary, TNFR2 targeted therapy may be a new approach to improve the efficacy of anti-tumor immunotherapy, as well as an adjuvant to improve the efficacy of other immune checkpoint inhibitors. This evidence concerns the gene TNFRSF1B and neoplasm.